Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Baxter
Boehringer Ingelheim
Merck
McKesson

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR TOPOSAR


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Toposar

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT05019716 ↗ Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma Not yet recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2022-04-29 This phase I/II trial tests the safety, side effects, and best dose of a new combination of drugs, ZEN003694, cisplatin, and etoposide in treating patients with NUT carcinoma (phase I), and identifies whether this combination therapy works to shrink tumor in these patients (phase II). Another purpose of this study is to see whether there are any changes in patient's tumor or blood characteristics (e.g. genes, molecules, etc.) due to combination therapy. ZEN003694 inhibits the production of certain growth-promoting proteins and may prevent proliferation of tumor cells that use those proteins for their growth. Chemotherapy drugs, such as etoposide and cisplatin, work by stopping or slowing the growth of cancer cells. Combination therapy with ZEN003694, etoposide and cisplatin may be effective in treating patients with NUT carcinoma.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Toposar

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003657 ↗ High-dose ICE With Amifostine Completed National Cancer Institute (NCI) Phase 2 1998-07-01 The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.
NCT00003657 ↗ High-dose ICE With Amifostine Completed Dana-Farber Cancer Institute Phase 2 1998-07-01 The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.
NCT00005803 ↗ Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Completed National Cancer Institute (NCI) Phase 1/Phase 2 1999-09-01 This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment. Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Toposar

Condition Name

Condition Name for Toposar
Intervention Trials
Recurrent Diffuse Large B-Cell Lymphoma 12
Refractory Diffuse Large B-Cell Lymphoma 10
Extensive Stage Lung Small Cell Carcinoma 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Toposar
Intervention Trials
Lymphoma 56
Leukemia 32
Lymphoma, Non-Hodgkin 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Toposar

Trials by Country

Trials by Country for Toposar
Location Trials
Canada 196
Australia 84
New Zealand 35
Puerto Rico 21
Japan 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Toposar
Location Trials
California 64
New York 61
Texas 61
Washington 58
Ohio 55
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Toposar

Clinical Trial Phase

Clinical Trial Phase for Toposar
Clinical Trial Phase Trials
Phase 3 27
Phase 2/Phase 3 4
Phase 2 56
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Toposar
Clinical Trial Phase Trials
Recruiting 42
Active, not recruiting 37
Completed 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Toposar

Sponsor Name

Sponsor Name for Toposar
Sponsor Trials
National Cancer Institute (NCI) 110
Children's Oncology Group 18
M.D. Anderson Cancer Center 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Toposar
Sponsor Trials
Other 119
NIH 111
Industry 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
AstraZeneca
Dow
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.